Keywords: BioMarin, LEAD Therapeutics, M&A, LT-673, Huxley, Financial guidance, BMN 110, Morquio
BioMarin to acquire LEAD Therapeutics for $18 million plus $68 million more on milestone
Article | 05 February 2010
California, USA-based BioMarin Pharmaceutical has entered into a stock purchase agreement to acquire LEAD Therapeutics, a small private drug discovery ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
